[go: up one dir, main page]

BG101126A - The use of muramylpeptide compounds - Google Patents

The use of muramylpeptide compounds

Info

Publication number
BG101126A
BG101126A BG101126A BG10112697A BG101126A BG 101126 A BG101126 A BG 101126A BG 101126 A BG101126 A BG 101126A BG 10112697 A BG10112697 A BG 10112697A BG 101126 A BG101126 A BG 101126A
Authority
BG
Bulgaria
Prior art keywords
muramylpeptide
compounds
prophylaxy
treatment
isoglutam
Prior art date
Application number
BG101126A
Other languages
Bulgarian (bg)
Inventor
Philip Ledger
Original Assignee
Peptech (Uk) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptech (Uk) Limited filed Critical Peptech (Uk) Limited
Publication of BG101126A publication Critical patent/BG101126A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

The muramylpeptide compounds, and in particular N-acetyl-d-glucosaminyl-(1-4)-N-acetylmuramul-L-alanyl-D-isoglutam in (GMDP) are used for the treatment and prophylaxy of inflammatory dermatological conditions such as psoriasis and in the treatment and prophylaxy of immunodependent diseases of the skin and the mucuous membranes.
BG101126A 1994-07-11 1997-01-10 The use of muramylpeptide compounds BG101126A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9413935A GB9413935D0 (en) 1994-07-11 1994-07-11 Use of maramyl peptide compounds
CN95194573A CN1155245A (en) 1994-07-11 1995-07-10 Use of muramyl peptide compounds
PCT/GB1995/001619 WO1996001645A1 (en) 1994-07-11 1995-07-10 Use of muramyl peptide compounds

Publications (1)

Publication Number Publication Date
BG101126A true BG101126A (en) 1997-09-30

Family

ID=25743816

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101126A BG101126A (en) 1994-07-11 1997-01-10 The use of muramylpeptide compounds

Country Status (13)

Country Link
EP (1) EP0768888A1 (en)
JP (1) JPH10505580A (en)
CN (1) CN1155245A (en)
AU (1) AU2893595A (en)
BG (1) BG101126A (en)
CA (1) CA2194678A1 (en)
CZ (1) CZ4797A3 (en)
GB (1) GB9413935D0 (en)
HU (1) HUT77290A (en)
IL (1) IL114542A0 (en)
SK (1) SK2697A3 (en)
WO (1) WO1996001645A1 (en)
ZA (1) ZA955763B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1038532A4 (en) * 1997-04-11 2003-08-13 Oleg Vitallievich Kaljuzhin Immunomodulator and pharmaceutical compositions with antitumor properties, and a food additive
GB9710351D0 (en) * 1997-05-20 1997-07-16 Scotia Holdings Plc Glucosamine fatty acids
WO1999062537A1 (en) * 1998-06-04 1999-12-09 The Rockefeller University Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins
DE10106852A1 (en) * 2001-02-14 2002-09-05 T Luger Anti-inflammatory compounds
FR2899466B1 (en) * 2006-04-07 2008-09-26 Oreal USE OF C-GLYCOSIDE COMPOUND ACTIVATING AGENT AND REGULATOR OF SKIN IMMUNITY
US20120156137A1 (en) 2006-10-20 2012-06-21 Soo-Youl Kim Composition for treatment of atopic dermatitis comprising glucosamine and derivatives thereof and a method for treatment of atopic dermatitis using them
US8603978B2 (en) * 2006-12-01 2013-12-10 The United States of America, as represented by the Secretary, Department of Health and Humand Services Use of muramyl dipeptide (MDP) for treating inflammation
FR2933984B1 (en) * 2008-07-15 2013-01-04 Univ Bourgogne D, D MURAMYLDIPEPTIDE, DERIVATIVE COMPOUNDS AND USE FOR THE TREATMENT OF ATHEROMOUS PLAQUES
US10610564B2 (en) 2015-02-26 2020-04-07 Stc.Unm IRGM and precision autophagy controls for antimicrobial and inflammatory disease states and methods of detection of autophagy
CN108884132B (en) 2015-12-10 2022-10-04 巴拉特生物技术国际有限公司 Muramyl peptide derivatives a compound their synthesis and their use
EP3389643B1 (en) 2015-12-15 2023-05-03 Bharat Biotech International Limited Novel muramyl peptide derivative compound, synthesis and uses thereof
CN116077439A (en) 2016-04-29 2023-05-09 西奈山伊坎医学院 Targeting the innate immune system to induce long-term tolerance and address macrophage accumulation in atherosclerosis
IL306006A (en) 2021-03-19 2023-11-01 Trained Therapeutix Discovery Inc Compounds for regulating trained immunity, and their methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357322A (en) * 1980-07-29 1982-11-02 Syntex (U.S.A.) Inc. Method of preventing, reducing or inhibiting inflammation
US4698330A (en) * 1983-06-27 1987-10-06 President & Fellows Of Harvard College Somnogenic compositions and method of use
HU205147B (en) * 1989-06-29 1992-03-30 Sandoz Ag Process for producing muramyl dipeptide derivative and pharmaceutical compostions comprising same
US5506204A (en) * 1991-11-19 1996-04-09 Peptech (Uk) Limited Muramyl compounds for treatment of septic shock
GB9204354D0 (en) * 1992-02-28 1992-04-08 Biokine Tech Ltd Compounds for medicinal use
GB9320820D0 (en) * 1993-10-08 1993-12-01 Biokine Tech Ltd Compounds for medicinal use
GB9326518D0 (en) * 1993-12-29 1994-03-02 Sandoz Ltd Organic compounds

Also Published As

Publication number Publication date
HU9700071D0 (en) 1997-02-28
GB9413935D0 (en) 1994-08-31
IL114542A0 (en) 1995-11-27
CZ4797A3 (en) 1997-07-16
HUT77290A (en) 1998-03-30
CA2194678A1 (en) 1996-01-25
JPH10505580A (en) 1998-06-02
EP0768888A1 (en) 1997-04-23
WO1996001645A1 (en) 1996-01-25
SK2697A3 (en) 1997-08-06
AU2893595A (en) 1996-02-09
ZA955763B (en) 1997-01-13
CN1155245A (en) 1997-07-23

Similar Documents

Publication Publication Date Title
TR199901172T2 (en) Newly substituted pyrazole derivatives.
AU1049788A (en) Methods and peptides for the treatment of non-ige-mediated diseases
BG104056A (en) Triazole compounds and their use as dopamine-d3-ligands
MY106272A (en) Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants.
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
MY121548A (en) Compounds and methods for the treatment of cancer
AU5624699A (en) Use of 5ht-6 antagonists
MY113079A (en) Estrogen agonists as remedies for cardiovascular diseases
DE69905368D1 (en) Oxydiertes thymosin beta 4
DE60124715D1 (en) PRODUCTION OF BETA ENDORPHINE
BG101126A (en) The use of muramylpeptide compounds
AU1798995A (en) Use of extracts of filamentous bacteria as cosmetic agents to combat ageing of the skin
WO1997004788A3 (en) Use of calendula glycosides for the treatment of psoriasis
DK0942741T3 (en) Lectin preparations and uses thereof
DK0700898T3 (en) L-carnitine salt and cosmetic and pharmaceutical preparations containing the same, for the treatment of dermatoses.
ZA978639B (en) Use of 1-hydroxy-2-pyridones for the treatment of skin infections.
ITRM960364A0 (en) ACTIVE THERAPEUTIC AGENT FOR THE TREATMENT OF NEURONAL DEGENERATIVE DISEASES.
NO991734L (en) Pyrazolinones for the treatment of potency disorders
DK0700897T3 (en) L-carnitine salt and cosmetic and pharmaceutical preparations containing the same for the treatment of skin diseases
TR199900662T2 (en) The use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis
TR200200278T2 (en) Calcilitic compositions
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
AU5630399A (en) Use of at least a10-hydroxy-2- decenoic acid derivative in composition for promoting skin scaling
MXPA02003731A (en) Novel fusidic acid derivatives.
NO970185L (en) Use of (S) -adenosyl-L-methionine (SAMe) and its physiologically compatible salts for the treatment of reperfusion injury triggered by temporal-focal ischemia